Chapter

Transfusion of plasma, platelets, and Red Blood Cells in a 1:1:1 versus a 1:1:2 Ration and Mortality in Patients with Severe Trauma

Yuk Ming Liu and Kathryn Butler

in 50 Studies Every Intensivist Should Know

Published on behalf of Oxford University Press

Published in print January 2018 | ISBN: 9780190467654
Published online February 2018 | e-ISBN: 9780190467685 | DOI: https://dx.doi.org/10.1093/med/9780190467654.003.0041

Series: Fifty Studies Every Doctor Should Know

Transfusion of plasma, platelets, and Red Blood Cells in a 1:1:1 versus a 1:1:2 Ration and Mortality in Patients with Severe Trauma

More Like This

Show all results sharing these subjects:

  • Critical Care
  • Anaesthetics
  • Primary Care

GO

Show Summary Details

Preview

This chapter provides a summary of the landmark study known as the PROPPR trial. How effective and safe is rapid transfusion of patients with severe traumatic hemorrhage using plasma, platelets, and red blood cells in a 1:1:1 ratio compared to a 1:1:2 ratio? Starting with that question, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. The chapter briefly reviews other relevant studies and information, discusses implications, and concludes with a relevant clinical case. A growing body of literature suggests that massive transfusion protocols confer mortality benefits for trauma patients in hemorrhagic shock; however, such protocols still require standardization. In the PROPPR trial, there was suggestion of improved hemostasis and less death from exsanguinations with a 1:1:1 transfusion ratio versus a 1:1:2 approach; however, further trials are warranted.

Chapter.  1731 words.  Illustrated.

Subjects: Critical Care ; Anaesthetics ; Primary Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or purchase to access all content.